Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates

Clinical and Vaccine Immunology

Volumn 17, Issue 1, 2010, Pages 73-79

  Cui, Changfa ^a,c   Carbis, Rodney ^a   So, Jung An ^a   Jang, Hyun ^a   Czerkinsky, Cecil ^a   Szu, Shousun C ^b   Clemens, John D ^a  

^a International Vaccine Institute   (South Korea)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPIC ACID; ANTIBODY; BACTERIAL PROTEIN; DIPHTHERIA TOXOID; POLYSACCHARIDE; RECOMBINANT EXOPROTEIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA; SEROTYPE; TYPHOID FEVER;

ANIMALS; ANTIBODIES, BACTERIAL; DIPHTHERIA TOXOID; DRUG STABILITY; FEMALE; FREEZING; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MICE; POLYSACCHARIDES, BACTERIAL; SALMONELLA TYPHI; TYPHOID-PARATYPHOID VACCINES;

EID: 74549164361     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00266-09     Document Type: Article

References (54)

1. Alexander, H. E., G. Leidy, and C. MacPherson. 1946. Production of types a, b, c, d, e and f H. influenzae antibody for diagnostic and therapeutic purposes. J. Immunol. 54:207-211.
2. Bhutta, Z. A. 1996. Impact of age and drug resistance on mortality in typhoid fever. Arch. Dis. Child. 75:214-217.
3. Borrow, R., D. Goldblatt, N. Andrews, P. Richmond, J. Southern, and E. Miller. 2001. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J. Infect. Dis. 184:377-380.
4. Borrow, R., J. Southern, N. Andrews, N. Peake, R. Rahim, M. Acuna, S. Martin, E. Miller, and E. Kaczmarski. 2001. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine 19:3043-3050.
5. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
6. Calandra, G. B., L. J. Lukacs, L. C. Jonas, M. Santosham, J. I. Ward, D. P. Greenberg, R. S. Daum, H. Matthews, P. P. Vella, and J. L. Ryan. 1993. Anti-PRP antibody levels after a primary series of PRP-OMPC and persistence of antibody titres following primary and booster doses. Vaccine 11(Suppl. 1):S58-S62.
7. Canh, D. G., F. Y. Lin, V. D. Thiem, D. D. Trach, N. D. Trong, N. D. Mao, S. Hunt, R. Schneerson, J. B. Robbins, C. Chu, J. Shiloach, D. A. Bryla, M. C. Bonnet, D. Schulz, and S. C. Szu. 2004. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect. Immun. 72:6586-6588.
8. Chu, C., R. Schneerson, J. B. Robbins, and S. C. Rastogi. 1983. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect. Immun. 40: 245-256.
9. Claesson, B. A., R. Schneerson, T. Lagergard, B. Trollfors, J. Taranger, J. Johansson, D. Bryla, and J. B. Robbins. 1991. Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age. Pediatr. Infect. Dis. J. 10:560-564.
10. Crump, J. A., S. P. Luby, and E. D. Mintz. 2004. The global burden of typhoid fever. Bull. World Health Organ. 82:346-353.
11. DeRoeck, D., R. L. Ochiai, J. Yang, D. D. Anh, V. Alag, and J. D. Clemens. 2008. Typhoid vaccination: the Asian experience. Expert Rev. Vaccines 7:547-560.
12. Devi, S. J., J. B. Robbins, and R. Schneerson. 1991. Antibodies to poly[(2-8)-alpha-N-acetylneuraminic acid] and poly[(2-9)-alpha-N- acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc. Natl. Acad. Sci. USA 88:7175-7179.
13. Fattom, A., R. Schneerson, D. C. Watson, W. W. Karakawa, D. Fitzgerald, I. Pastan, X. Li, J. Shiloach, D. A. Bryla, and J. B. Robbins. 1993. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect. Immun. 61:1023-1032.
14. Ferreccio, C., M. M. Levine, A. Manterola, G. Rodriguez, I. Rivara, I. Prenzel, R. E. Black, T. Mancuso, and D. Bulas. 1984. Benign bacteremia caused by Salmonella typhi and paratyphi in children younger than 2 years. J. Pediatr. 104:899-901.
15. Gupta, A. 1994. Multidrug-resistant typhoid fever in children: epidemiology and therapeutic approach. Pediatr. Infect. Dis. J. 13:134-140.
16. Haeuw, J. F., C. Libon, L. Zanna, L. Goetsch, T. Champion, T. N. Nguyen, J. Y. Bonnefoy, N. Corvaia, and A. Beck. 2000. Physico-chemical characterization and immunogenicity studies of peptide and polysaccharide conjugate vaccines based on a promising new carrier protein, the recombinant Klebsiella pneumoniae OmpA. Dev. Biol. 103:245-250.
17. Hale, C., F. Bowe, D. Pickard, S. Clare, J. F. Haeuw, U. Powers, N. Menager, P. Mastroeni, and G. Dougan. 2006. Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis. Vaccine 24:4312-4320.
18. Ho, M. M., F. Mawas, B. Bolgiano, X. Lemercinier, D. T. Crane, R. Huskisson, and M. J. Corbel. 2002. Physico-chemical and immunological examination of the thermal stability of tetanus toxoid conjugate vaccines. Vaccine 20:3509-3522.
19. Ivanoff, B., M. M. Levine, and P. H. Lambert. 1994. Vaccination against typhoid fever: present status. Bull. World Health Organ. 72:957-971.
20. Jin, Z., G. A. Bohach, J. Shiloach, S. E. Norris, D. I. Freedberg, C. Deobald, B. Coxon, J. B. Robbins, and R. Schneerson. 2005. Conjugates of group A and W135 capsular polysaccharides of Neisseria meningitidis bound to recombinant Staphylococcus aureus enterotoxin C1: preparation, physicochemical characterization, and immunological properties in mice. Infect. Immun. 73:7887-7893.
21. Klugman, K. P., I. T. Gilbertson, H. J. Koornhof, J. B. Robbins, R. Schneerson, D. Schulz, M. Cadoz, and J. Armand. 1987. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet ii:1165-1169.
22. Klugman, K. P., H. J. Koornhof, J. B. Robbins, and N. N. Le Cam. 1996. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14:435-438.
23. Kossaczka, Z., F. Y. Lin, V. A. Ho, N. T. Thuy, P. Van Bay, T. C. Thanh, H. B. Khiem, D. D. Trach, A. Karpas, S. Hunt, D. A. Bryla, R. Schneerson, J. B. Robbins, and S. C. Szu. 1999. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect. Immun. 67:5806-5810.
24. Kossaczka, Z., S. Bystricky, D. A. Bryla, J. Shiloach, J. B. Robbins, and S. C. Szu. 1997. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect. Immun. 65:2088-2093.
25. Landy, M. 1957. Studies on Vi antigen. VII. Characteristics of the immune response in the mouse. Am. J. Hyg. 65:81-93.
26. Lin, F. Y., V. A. Ho, H. B. Khiem, D. D. Trach, P. V. Bay, T. C. Thanh, Z. Kossaczka, D. A. Bryla, J. Shiloach, J. B. Robbins, R. Schneerson, and S. C. Szu. 2001. The efficacy of a Salmonella typhi Vi conjugate vaccine in twoto-five-year-old children. N. Engl. J. Med. 344:1263-1269.
27. Mahle, W. T., and M. M. Levine. 1993. Salmonella typhi infection in children younger than five years of age. Pediatr. Infect. Dis. J. 12:627-631.
28. Mai, N. L., V. B. Phan, A. H. Vo, C. T. Tran, F. Y. Lin, D. A. Bryla, C. Chu, J. Schiloach, J. B. Robbins, R. Schneerson, and S. C. Szu. 2003. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N. Engl. J. Med. 349:1390-1391.
29. Murdoch, D. A., N. Banatvaia, A. Bone, B. I. Shoismatulloev, L. R. Ward, and E. J. Threlfall. 1998. Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan. Lancet 351:339.
30. Nolan, C. M., E. A. LaBorde, R. T. Howell, and J. B. Robbins. 1980. Identification of Salmonella typhi in faecal specimens by an antiserum-agar method. J. Med. Microbiol. 13:373-377.
31. Orthopoulos, G. V., M. C. Theodoridou, V. A. Ladis, D. K. Tsousis, and V. I. Spoulou. 2009. The effect of 23-valent pneumococcal polysaccharide vaccine on immunological priming induced by 7-valent conjugate vaccine in asplenic subjects with beta-thalassemia. Vaccine 27:350-354.
32. Paniagua, J., J. A. Garcia, C. R. Lopez, C. R. Gonzalez, A. Isibasi, and J. Kumate. 1992. Conjugate vaccines against bacterial infections: typhoid fever. Salud Publica Mex. 34:268-273. (In Spanish.)
33. Plikaytis, B. D., P. F. Holder, and G. M. Carlone. 1996. Program ELISA for Windows user's manual, version 1.00. Centers for Diease Control and Prevention, Atlanta, GA.
34. Rajajee, S., T. B. Anandi, S. Subha, and B. R. Vatsala. 1995. Patterns of resistant Salmonella typhi infection in infants. J. Trop. Pediatr. 41:52-54.
35. Rao, P. T., and K. V. Rao. 1959. Typhoid fever in children. Indian J. Pediatr. 26:258-264.
36. Robbins, J. B., and R. Schneerson. 1990. Polysaccharide-protein conjugates: a new generation of vaccines. J. Infect. Dis. 161:821-832.
37. Robbins, J. B., R. Schneerson, P. Anderson, and D. H. Smith. 1996. The 1996 Albert Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines. JAMA 276:1181-1185.
38. Robbins, J. B., R. Schneerson, S. C. Szu, and Y. H. Yang. 1986. Prospects for polysaccharide-protein conjugate vaccines. Ann. Sclavo Collana Monogr. 3:213-232.
39. Robbins, J. D., and J. B. Robbins. 1984. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J. Infect. Dis. 150:436-449.
40. Rose, M. A., R. Schubert, N. Strnad, and S. Zielen. 2005. Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine. Clin. Diagn. Lab. Immunol. 12:1216-1222.
41. Rothstein, E. P., R. P. Schiller, J. A. Girone, T. J. Hipp, R. L. Souder, H. H. Bernstein, D. V. Madore, C. L. Johnson, and D. H. Smith. 1991. Response of 7- to 15-month-old infants to sequential immunization with Haemophilus influenzae type b-CRM197 conjugate and polysaccharide vaccines. Am. J. Dis. Child. 145:898-900.
42. Rowe, B., L. R. Ward, and E. J. Threlfall. 1997. Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin. Infect. Dis. 24(Suppl. 1):S106-S109.
43. Saha, S. K., S. Y. Talukder, M. Islam, and S. Saha. 1999. A highly ceftriaxone-resistant Salmonella typhi in Bangladesh. Pediatr. Infect. Dis. J. 18:387.
44. Schneerson, R., O. Barrera, A. Sutton, and J. B. Robbins. 1980. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152:361-376.
45. Singhal, T., Y. Amdekar, and R. Agarwal. 2009. IAP guidebook on immunization: IAP Committee on Immunization 2007-2008, p. 57. Jaypee, New Delhi, India.
46. Stormon, M. O., P. B. McIntyre, J. Morris, and B. Fasher. 1997. Typhoid fever in children: diagnostic and therapeutic difficulties. Pediatr. Infect. Dis. J. 16:713-714.
47. Szu, S. C., S. Bystricky, M. Hinojosa-Ahumada, W. Egan, and J. B. Robbins.1994. Synthesis and some immunologic properties of an O-acetyl pectin [poly(1→4)-alpha-D-GalpA]-protein conjugate as a vaccine for typhoid fever. Infect. Immun. 62:5545-5549.
48. Szu, S. C., X. R. Li, R. Schneerson, J. H. Vickers, D. Bryla, and J. B. Robbins. 1989. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to highor lower-molecular-weight Vi. Infect. Immun. 57:3823-3827.
49. Szu, S. C., A. L. Stone, J. D. Robbins, R. Schneerson, and J. B. Robbins. 1987. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J. Exp. Med. 166:1510-1524.
50. Szu, S. C., D. N. Taylor, A. C. Trofa, J. D. Clements, J. Shiloach, J. C. Sadoff, D. A. Bryla, and J. B. Robbins. 1994. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect. Immun. 62:4440-4444.
51. Verma, M., Y. Parashar, A. Singh, and R. Kamoji. 2007. Current pattern of enteric fever: a prospective clinical and microbiological study. J. Indian Med. Assoc. 105:582, 584, 586.
52. WHO. 2008. Typhoid vaccines: WHO position paper. Wkly. Epidemiol. Rec. 83:49-59.
53. WHO. 2003. WHO background document: The diagnosis, treatment and prevention of typhoid fever. WHO, Geneva, Switzerland.
54. WHO. 1994. WHO technical report series, no. 840, 1994. Requirements for Vi polysaccharide typhoid vaccine. WHO, Geneva, Switzerland.